BTK Inhibitors Versus Venetoclax as First- or Second-Line Therapy in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Evidence Study.

ABSTRACT:

SUBMITTER: Roeker LE 

PROVIDER: S-EPMC11886488 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature